Intelligence · Clinical Pipeline
Anaxis Pharma Pipeline
All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.
- Programs
- 642
Quick answer
Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparing Alverine citrate/Simeticone 60 mg/300 mg soft capsules to Meteospasmyl 60 mg/300 mg soft capsules in healthy male and female subjects under fed conditions.
Lacuna Pharma Pty Ltd
Not applicable (submitted trial is a bioavailability study in healthy subjects)
1 trial -
An open, single arm, single-center, Phase 1 trial investigating the effect of 7-days-repeated administration of linaprazan glurate on the pharmacokinetics of repeated doses of an approved antibiotic in healthy participants
Lacuna Pharma Pty Ltd
Helicobacter pylori infection, GERD
1 trial -
An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers under fasting conditions.
Lacuna Pharma Pty Ltd
inteneded for treatment of - active rheumatoid arthritis in adult patients, - polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal anti-inflammatory drugs has been inadequate, - severe recalcitrant disabling psoriasis which is not adequately responsive to other forms of therapy and severe psoriatic arthritis in adult patients, - mild-to-moderate Crohn’s disease, either alone or in combination with corticosteroids, in adult patients refractory or intolerant to thiopurines.
1 trial -
Bepranemab
Lacuna Pharma Pty Ltd
Progressive Supranuclear Palsy
1 trial -
Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in
Lacuna Pharma Pty Ltd
Hidradenitis suppurativa, Axial spondyloarthritis, Moderate to Severe Plaque Psoriasis, Psoriatic arthritis
1 trial -
Bioequivalence of Cladribine 10 mg from two different products
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 10 mg/mL Oral Solution in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 20 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Lisdexamfetamine dimesylate 70 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 20 mg Tablets in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Ruxolitinib 25 mg Tablets in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition
1 trial -
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets versus Xeljanz® 10 mg Film-Coated Tablets in Healthy Subjects Under Fed Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Bioequivalence study of GP-IMP-001 with regards to reference product
Lacuna Pharma Pty Ltd
healthy volunteers
1 trial -
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen
Lacuna Pharma Pty Ltd
Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency
1 trial -
Ceftobiprole OATP1B interaction study
Lacuna Pharma Pty Ltd
Community-acquired bacterial pneumonia
1 trial -
Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.
Lacuna Pharma Pty Ltd
NASH
1 trial -
Clinical study to evaluate the safety of investigational medicinal product called AD-O51.4 in patients with advanced malignancies
Lacuna Pharma Pty Ltd
Patients suffering from cancer without further treatment options.
1 trial -
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditions
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Comparative Bioavailability of Ruxolitinib 20 mg Film-Coated Tablets in Healthy Participants Under Fasting Conditions.
Lacuna Pharma Pty Ltd
No medical condition.
1 trial -
Creon 25.000, harde maagsapresistente capsules 25.000 eenheden, Creon 50000 Ph.Eur. lipase units, Creon 25000 Ph.Eur. lipase units, Creon 10000 Ph.Eur. lipase units, Creon 75000 Ph.Eur. lipase units, Creon® 10000 Capsules
Lacuna Pharma Pty Ltd
patients with cystic fibrosis suffering from pancreatic exocrine insufficiency
1 trial -
DMT in healthy subjects
Lacuna Pharma Pty Ltd
Stroke
1 trial -
DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS
Lacuna Pharma Pty Ltd
Hypolactasia
1 trial -
Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis
Lacuna Pharma Pty Ltd
Lupus Nephritis
1 trial -
Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in Healthy Participants
Lacuna Pharma Pty Ltd
Pruritus
1 trial -
Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria
Lacuna Pharma Pty Ltd
Phenylketonuria
1 trial -
Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics
Lacuna Pharma Pty Ltd
Phase I study in healthy male volunteers. Intended indication: Duchenne muscular dystrophy and Becker muscular dystrophy
1 trial -
First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients
Lacuna Pharma Pty Ltd
Olmsted syndrome
1 trial -
First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)
Lacuna Pharma Pty Ltd
Parkinson's disease
1 trial -
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
Lacuna Pharma Pty Ltd
Atopic Dermatits
1 trial -
First-in-human Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of the Adjuvanted Universal Influenza Vaccine “fH1/DSP-0546LP” in Healthy Adults
Lacuna Pharma Pty Ltd
Influenza
1 trial -
INZ-701, INZ-701
Lacuna Pharma Pty Ltd
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
1 trial -
Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Lacuna Pharma Pty Ltd
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
1 trial
Frequently asked questions
How many pipeline programs does Anaxis Pharma have?
642 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs